Do you want to read an article? Please log in or register.
Long-term outcomes of a cascading salvage strategy for high-risk non-muscle-invasive bladder cancer
Genitourinary Cancer
Related content
COMMENTED
Genitourinary Cancer
Gemcitabine and docetaxel for high-risk non-muscle-invasive bladder cancer: EuroGemDoce group results
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
BJU Int
Scilipoti P, Longoni M, de Angelis M, Zaurito P, Massiet A, Dutto D, Soria F, Álvarez-Maestro M, Bazán AA, Pradere B, Klatte T, Contieri R, Hurle R, Krajewski W, Subiela JD, Pichler R, Szostek A, Marcq G, Elena JLR, Aranda J, Gontero P, Rouprêt M, Shariat SF, Necchi A, Montorsi F, Briganti A, Xylinas E, Moschini M, EuroGemDoce Study Group Collaborators, European Association of Urology ‐ Young Academic Urologists (EAU‐YAU), Urothelial Carcinoma Working Group
doi: 10.1111/bju.16645
Genitourinary Cancer
Long-term Outcomes and Prognostic Impact of Residual Cancer Burden After Intensified Neoadjuvant Therapy in High-risk Prostate Cancer
Eur Urol
Ravi P, Kwak L, Acosta AM, Rastogi S, Xie W, Abdelnaser A, Einstein DJ, Chang P, Wagner AA, McKay RR, Kibel AS, Taplin ME
doi: 10.1016/j.eururo.2025.01.015
Genitourinary Cancer
Gemcitabine versus Bacillus Calmette-Guerin for Intravesical Therapy in Treatment-Naïve Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
J Urol
Khene ZE, Bhanvadia R, Attia S, Ito W, Trevino I, Woldu SL, Margulis V, Lotan Y
doi: 10.1097/JU.0000000000004472
Genitourinary Cancer
Cisplatin-ineligible patients with muscle-invasive bladder cancer demonstrate poor long-term survival following immediate radical cystectomy
BJU Int
Fazili A, Jazayeri SB, Rose KM, Guske C, Wen L, Durant A, Prunty M, Bukavina L, Tyson MD, Grass GD, Xu H, Spiess PE, Gilbert SM, Sexton WJ, Zemp L, Pessoa RR, Poch M, Lerner SP, Li R
doi: 10.1111/bju.16895
Genitourinary Cancer
A Systematic Review of Novel Intravesical Approaches for the Treatment of Patients with Non-muscle-invasive Bladder Cancer
Eur Urol
Ghodoussipour S, Bivalacqua T, Bryan RT, Li R, Mir MC, Palou J, Psutka SP, Sundi D, Tyson MD, Inman BA
doi: 10.1016/j.eururo.2025.02.010
Genitourinary Cancer
Defining statistical cure in patients with T1 high-grade non-muscle-invasive bladder carcinoma treated with BCG immunotherapy
BJU Int
Subiela JD, de la Parra I, Taborda J, Medina AA, Pichler R, Krajewski W, Ojeda CM, Mardomingo AF, Durán PDO, Pérez EL, González-Padilla DA, Aumatell J, Mori K, Scilipoti P, Longoni M, de Angelis M, Caño-Velasco J, Puentedura AL, Pujol LP, Contieri R, Gallioli A, Tukiendorf A, D'Andrea D, Teoh JY, Afferi L, Del Giudice F, Marcq G, Albisinni S, Soria F, Mertens LS, Laukhtina E, Tully K, Mari A, Guerrero-Ramos F, Alvarez-Maestro M, Martín CC, Melendres FA, Buisan O, López-González JA, Dominguez-Escrig JL, Aranda J, Elena JLR, Basile G, Santos VGD, Moschini M, Pradere B, Acosta EA, Palacio FL, Puig AC, Gajate P, Saiz A, Gontero P, Revilla FJB, From Young Academic Urologist: Urothelial Carcinoma Working Group
doi: 10.1111/bju.16913
Multiple Myeloma (MM)
Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health database
Blood Cancer J
Rajkumar SV, Mateos MV, Schaeffer M, Lin X, Bathija S, Gupta-Werner N, Lam A, Carson R, Dennis R, Kaila S, Matt K, Duran J, Lonial S
doi: 10.1038/s41408-024-01170-z
Genitourinary Cancer
External validation of the Uromonitor®-version 2 urine test as a biomarker for optimisation of non-muscle-invasive bladder cancer management
BJU Int
Rubio-Briones J, Guerrero Ramos F, Mercadé Sánchez A, Bezana Abadía I, Rodríguez RM, Alcaraz A, Miqueleiz Legaz M, Lozano F, Arrabal Martín M, Luis Cardo A, Gonzalo Rodríguez V, Caño Velasco J, Serrano Liesa M, Ferreiro Pareja C, Espílez Ortiz R, de González-Valcárcel de Torres I, Sánchez Zalabardo D, Esquinas C, Mengual L, Borque-Fernando A, Esteban Escaño LM, Palou Redorta J, Witjes F, Martínez Piñeiro L
doi: 10.1111/bju.70010
Genitourinary Cancer
Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials
J Clin Oncol
Armstrong AJ, Liu VYT, Selvaraju RR, Chen E, Simko JP, DeVries S, Sartor O, Sandler HM, Mohamad O, Huang HC, Griffin J, Yamashita R, Esteva A, Tran PT, Spratt DE, Carson JH, Peters C, Gore E, Lee SP, Monson JM, Augspurger ME, El-Gayed A, Rodgers JP, McKay R, Morgan T, Feng FY, Nguyen PL
doi: 10.1200/JCO.24.00365